Press Releases

Date	Title and Summary	Additional Formats
April 10, 2017	Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs	View HTML Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
March 28, 2017	Vericel to Present at the 16th Annual Needham Healthcare Conference	View HTML Vericel to Present at the 16th Annual Needham Healthcare Conference
March 23, 2017	Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association	View HTML Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
March 10, 2017	Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results	View HTML Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results
March 3, 2017	Vericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017	View HTML Vericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
February 27, 2017	Vericel to Present at Multiple Upcoming Investor Conferences	View HTML Vericel to Present at Multiple Upcoming Investor Conferences
February 21, 2017	Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy	View HTML Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
February 1, 2017	Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee	View HTML Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
December 21, 2016	Vericel Corporation Announces Exercise of Underwriters' Over-Allotment Option and Closing of $20 Million Offering of Common Stock	View HTML Vericel Corporation Announces Exercise of Underwriters' Over-Allotment Option and Closing of $20 Million Offering of Common Stock
December 16, 2016	Vericel Corporation Prices $17 Million Public Offering of Common Stock	View HTML Vericel Corporation Prices $17 Million Public Offering of Common Stock

Investor Relations

Press Releases

Company Presentation